REZN Stock Overview
The Hash Corporation focuses on the production and sale of cannabis-based hashish and other cannabis products in Canada.
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.005|
|52 Week High||CA$0.025|
|52 Week Low||CA$0.005|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||-75.00%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-92.86%|
Recent News & Updates
|REZN||CA Pharmaceuticals||CA Market|
Return vs Industry: REZN underperformed the Canadian Pharmaceuticals industry which returned -64.8% over the past year.
Return vs Market: REZN underperformed the Canadian Market which returned -2.5% over the past year.
|REZN Average Weekly Movement||n/a|
|Pharmaceuticals Industry Average Movement||12.7%|
|Market Average Movement||10.1%|
|10% most volatile stocks in CA Market||18.3%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: Insufficient data to determine REZN's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine REZN's volatility change over the past year.
About the Company
The Hash Corporation focuses on the production and sale of cannabis-based hashish and other cannabis products in Canada. The company was formerly known as Senternet Phi Gamma Inc. and changed its name to The Hash Corporation in July 2019. The Hash Corporation was incorporated in 1967 and is headquartered in Toronto, Canada.
Hash Fundamentals Summary
|REZN fundamental statistics|
Is REZN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|REZN income statement (TTM)|
|Cost of Revenue||CA$787.94k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0081|
|Net Profit Margin||-165.57%|
How did REZN perform over the long term?See historical performance and comparison
Is REZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for REZN?
Other financial metrics that can be useful for relative valuation.
|What is REZN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does REZN's PS Ratio compare to its peers?
|REZN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SE Sweet Earth Holdings
PULL Pure Extracts Technologies
VIN Vinergy Capital
WIB West Island Brands
Price-To-Sales vs Peers: REZN is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (5.9x).
Price to Earnings Ratio vs Industry
How does REZN's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: REZN is good value based on its Price-To-Sales Ratio (1x) compared to the Canadian Pharmaceuticals industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is REZN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate REZN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of REZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate REZN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate REZN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Hash forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hash has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Hash performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REZN is currently unprofitable.
Growing Profit Margin: REZN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: REZN is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.
Accelerating Growth: Unable to compare REZN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REZN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: REZN has a negative Return on Equity (-493%), as it is currently unprofitable.
Discover strong past performing companies
How is Hash's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: REZN's short term assets (CA$639.4K) exceed its short term liabilities (CA$342.3K).
Long Term Liabilities: REZN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: REZN's net debt to equity ratio (18%) is considered satisfactory.
Reducing Debt: REZN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REZN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: REZN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 63% each year
Discover healthy companies
What is Hash current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Hash Dividend Yield vs Market|
|Market Bottom 25% (CA)||1.9%|
|Market Top 25% (CA)||5.9%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Hash)||n/a|
Notable Dividend: Unable to evaluate REZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REZN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REZN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as REZN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Savoie has been Chief Executive Officer and Director of The Hash Corporation (formerly, Senternet Phi Gamma Inc.) since July 8, 2019.
Experienced Management: REZN's management team is considered experienced (3.3 years average tenure).
Experienced Board: REZN's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The Hash Corporation's employee growth, exchange listings and data sources
- Name: The Hash Corporation
- Ticker: REZN
- Exchange: CNSX
- Founded: 1967
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$1.401m
- Shares outstanding: 280.12m
- Website: https://www.thehashcorporation.com
- The Hash Corporation
- 1 Adelaide Street East
- Suite 801
- M5C 2V9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|REZN||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Jun 2021|
|REZN.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jun 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/05 00:00|
|End of Day Share Price||2022/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.